Atrás
Rango del Día
$181.81
$188.93
Rango de 52 Semanas
$152.33
$246.33
Volumen
526,900
Promedio 50D / 200D
$207.33
/
$200.41
Cierre Anterior
$188.09
Historial de Precios
Tendencias Financieras
Comparación con Pares
vs mediana del sector Healthcare (627 pares)
| Métrica | Acción | Mediana del Sector |
|---|---|---|
| P/E | 7.9 | 0.4 |
| P/B | 1.6 | 2.9 |
| ROE % | 21.4 | 3.9 |
| Net Margin % | 8.6 | 3.8 |
| Rev Growth 5Y % | 8.3 | 10.0 |
| D/E | 0.8 | 0.2 |
Precio Objetivo de Analistas
Hold
$245.67
+32.1%
Low: $219.00
High: $274.00
P/E Futuro
8.0
EPS Futuro
$23.44
Crecimiento EPS (est.)
+0.0%
Ingresos Est.
18 B
Estimaciones de Ganancias
| Período | EPS Est. | Ingresos Est. | Analistas |
|---|---|---|---|
| FY2029 |
$28.77
$27.74 – $29.24
|
21 B | 4 |
| FY2028 |
$28.25
$26.68 – $31.03
|
20 B | 6 |
| FY2027 |
$25.57
$23.79 – $28.09
|
19 B | 11 |
Puntos Clave
Revenue grew 8.26% annually over 5 years — modest growth
Earnings grew 30.36% over the past year
ROE of 21.36% indicates high profitability
Generating 849.25M in free cash flow
P/E of 7.94 — trading at a low valuation
PEG of 0.26 suggests growth is underpriced
Crecimiento
Revenue Growth (5Y)
8.26%
Revenue (1Y)9.71%
Earnings (1Y)30.36%
FCF Growth (3Y)27.22%
Calidad
Return on Equity
21.36%
ROIC11.70%
Net Margin8.57%
Op. Margin11.48%
Seguridad
Debt / Equity
0.76
Current Ratio1.05
Interest Coverage12.68
Valoración
P/E Ratio
7.94
P/B Ratio1.62
EV/EBITDA8.62
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 9.71% | Revenue Growth (3Y) | 10.27% |
| Earnings Growth (1Y) | 30.36% | Earnings Growth (3Y) | 44.02% |
| Revenue Growth (5Y) | 8.26% | Earnings Growth (5Y) | 10.69% |
| Profitability | |||
| Revenue (TTM) | 17.36B | Net Income (TTM) | 1.49B |
| ROE | 21.36% | ROA | 9.33% |
| Gross Margin | 90.45% | Operating Margin | 11.48% |
| Net Margin | 8.57% | Free Cash Flow (TTM) | 849.25M |
| ROIC | 11.70% | FCF Growth (3Y) | 27.22% |
| Safety | |||
| Debt / Equity | 0.76 | Current Ratio | 1.05 |
| Interest Coverage | 12.68 | Dividend Yield | 0.00% |
| Valuation | |||
| P/E Ratio | 7.94 | P/B Ratio | 1.62 |
| P/S Ratio | 0.68 | PEG Ratio | 0.26 |
| EV/EBITDA | 8.62 | Dividend Yield | 0.00% |
| Market Cap | 11.82B | Enterprise Value | 17.19B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 17.36B | 15.83B | 14.28B | 13.40B | 12.64B |
| Net Income | 1.49B | 1.14B | 717.80M | 675.61M | 991.59M |
| EPS (Diluted) | 23.10 | 16.82 | 10.23 | 9.14 | 11.82 |
| Gross Profit | 15.71B | 14.24B | 12.75B | 11.93B | 11.21B |
| Operating Income | 1.99B | 1.68B | 1.18B | 1.00B | 1.36B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 15.96B | 14.47B | 13.97B | 13.49B | 13.09B |
| Total Liabilities | 8.55B | 7.71B | 7.77B | 7.52B | 6.90B |
| Shareholders' Equity | 7.28B | 6.67B | 6.15B | 5.92B | 6.09B |
| Total Debt | 5.51B | 4.96B | 5.37B | 5.27B | 4.56B |
| Cash & Equivalents | 137.80M | 125.98M | 119.44M | 102.82M | 115.30M |
| Current Assets | 3.41B | 2.82B | 2.81B | 2.54B | 2.26B |
| Current Liabilities | 3.24B | 2.21B | 2.01B | 1.91B | 1.98B |
Puntuaciones de Estrategias
This stock passed the criteria for 4 strategies
Score = fit strength (0–100)
Rank = position among all matches
Actividad Reciente
Entró
Contrarian Investing (David Dreman)
Mar 25, 2026
Entró
Balanced Risk
Mar 25, 2026
Entró
Lower Risk
Mar 25, 2026
Entró
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026